The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (with one abstention) on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list for ulcerative colitis use, following its earlier removal from Category 2 status in April 2026. This advisory step followed 2023 placement of multiple peptides in Category 2 over immunogenicity risks, peptide impurities, and limited human data. Actual Category 1 eligibility requires subsequent FDA rulemaking with notice-and-comment procedures, typically spanning several additional months. Market positioning reflects trader focus on whether final agency action occurs before any specified deadline, amid ongoing review of related peptides like KPV and TB-500.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডনতুন
Aug 31, 2026
August 31, 2026
4%
December 31, 2026
48%
$2,860 Vol.
August 31, 2026
$1,143 Vol.
4%
December 31, 2026
$1,716 Vol.
48%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (with one abstention) on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list for ulcerative colitis use, following its earlier removal from Category 2 status in April 2026. This advisory step followed 2023 placement of multiple peptides in Category 2 over immunogenicity risks, peptide impurities, and limited human data. Actual Category 1 eligibility requires subsequent FDA rulemaking with notice-and-comment procedures, typically spanning several additional months. Market positioning reflects trader focus on whether final agency action occurs before any specified deadline, amid ongoing review of related peptides like KPV and TB-500.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Jun 22, 2026, 10:10 PM ET
ভলিউম
$2,860শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (with one abstention) on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list for ulcerative colitis use, following its earlier removal from Category 2 status in April 2026. This advisory step followed 2023 placement of multiple peptides in Category 2 over immunogenicity risks, peptide impurities, and limited human data. Actual Category 1 eligibility requires subsequent FDA rulemaking with notice-and-comment procedures, typically spanning several additional months. Market positioning reflects trader focus on whether final agency action occurs before any specified deadline, amid ongoing review of related peptides like KPV and TB-500.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
ভলিউম
$2,860শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (with one abstention) on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list for ulcerative colitis use, following its earlier removal from Category 2 status in April 2026. This advisory step followed 2023 placement of multiple peptides in Category 2 over immunogenicity risks, peptide impurities, and limited human data. Actual Category 1 eligibility requires subsequent FDA rulemaking with notice-and-comment procedures, typically spanning several additional months. Market positioning reflects trader focus on whether final agency action occurs before any specified deadline, amid ongoing review of related peptides like KPV and TB-500.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা